JP2015517484A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517484A5
JP2015517484A5 JP2015510875A JP2015510875A JP2015517484A5 JP 2015517484 A5 JP2015517484 A5 JP 2015517484A5 JP 2015510875 A JP2015510875 A JP 2015510875A JP 2015510875 A JP2015510875 A JP 2015510875A JP 2015517484 A5 JP2015517484 A5 JP 2015517484A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
sequence
peptide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015510875A
Other languages
English (en)
Japanese (ja)
Other versions
JP5982562B2 (ja
JP2015517484A (ja
Filing date
Publication date
Priority claimed from GB201208293A external-priority patent/GB201208293D0/en
Application filed filed Critical
Publication of JP2015517484A publication Critical patent/JP2015517484A/ja
Publication of JP2015517484A5 publication Critical patent/JP2015517484A5/ja
Application granted granted Critical
Publication of JP5982562B2 publication Critical patent/JP5982562B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015510875A 2012-05-11 2013-05-09 ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途 Expired - Fee Related JP5982562B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201208293A GB201208293D0 (en) 2012-05-11 2012-05-11 Hydrochlorice salt of peptide
GB1208293.9 2012-05-11
PCT/GB2013/051201 WO2013167897A1 (en) 2012-05-11 2013-05-09 Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy

Publications (3)

Publication Number Publication Date
JP2015517484A JP2015517484A (ja) 2015-06-22
JP2015517484A5 true JP2015517484A5 (enExample) 2016-06-30
JP5982562B2 JP5982562B2 (ja) 2016-08-31

Family

ID=46396890

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015510875A Expired - Fee Related JP5982562B2 (ja) 2012-05-11 2013-05-09 ペプチドの塩酸塩及び他のペプチドとの併用によるその免疫治療用途

Country Status (17)

Country Link
US (1) US9657061B2 (enExample)
EP (1) EP2847209B8 (enExample)
JP (1) JP5982562B2 (enExample)
KR (1) KR20150014955A (enExample)
CN (1) CN104428311B (enExample)
AU (1) AU2013257784A1 (enExample)
BR (1) BR112014028130A2 (enExample)
CA (1) CA2873120A1 (enExample)
EA (1) EA201492068A1 (enExample)
GB (2) GB201208293D0 (enExample)
HK (1) HK1201850A1 (enExample)
IL (1) IL235388A (enExample)
IN (1) IN2014DN09367A (enExample)
MX (1) MX2014013394A (enExample)
SG (1) SG11201407446TA (enExample)
WO (1) WO2013167897A1 (enExample)
ZA (1) ZA201408290B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211754T1 (hr) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
DK3388075T5 (da) 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2021038431A1 (en) * 2019-08-26 2021-03-04 Auro Peptides Ltd An improved process for the preparation of etelcalcetide hydrochloride
WO2021137160A1 (en) * 2019-12-31 2021-07-08 Pfizer R&D Uk Limited Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
TWI792442B (zh) * 2021-07-23 2023-02-11 建誼生技股份有限公司 依特卡肽鹽酸鹽之製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453539B1 (en) * 2001-12-05 2008-11-19 Circassia Limited Immunotherapeutic methods and systems
MX2008009125A (es) 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
DK2083856T3 (da) * 2007-08-15 2011-01-24 Circassia Ltd Peptider til desensibilisering mod allergener
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CA2795047C (en) * 2010-03-31 2019-04-09 Stabilitech Ltd. Stabilised liquid formulations

Similar Documents

Publication Publication Date Title
JP2015517484A5 (enExample)
NZ759512A (en) Delayed release compositions of linaclotide
PE20241305A1 (es) Analogos de amilina
PH12018550201A1 (en) Hepatitis b antiviral agents
JP2015078230A5 (enExample)
PH12018502465A1 (en) Mic-1 compounds and use thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PH12018501236A1 (en) Pharmaceutical composition comprising a potent inhibitor urat1
WO2015114395A9 (en) Process for the preparation of vortioxetine salts
JP2015513318A5 (enExample)
JP2020513418A5 (enExample)
PH12013501442B1 (en) Immunosuppressant formulations
MX2021006969A (es) Ligante peptidico.
EP4653537A3 (en) Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
TW201613557A (en) Stable aqueous recombinant protein formulations
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
WO2013021284A3 (en) Anti-il-6 vaccine composition
JP2018529626A5 (enExample)
WO2012162637A3 (en) Vaccine adjuvants from self-assembling peptides
JP2013542196A5 (enExample)
JP2017007966A5 (enExample)
JP2016160183A5 (ja) 筋萎縮抑制剤及び筋萎縮抑制用飲食品
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX2013003551A (es) Formas en estado solido de un potente inhibidor del vch.